Literature DB >> 7505364

Receptor mechanism of thrombin-induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs.

D D Ku1, J K Zaleski.   

Abstract

We previously reported that thrombin produces endothelium-dependent relaxation and endothelium-independent constrictions in canine coronary arteries. To determine whether these opposing vascular effects of thrombin are mediated by the same receptor mechanism, but at different cell types, we investigated the effects of thrombin receptor agonist peptide (TRAP) on isolated canine coronary arteries with and without intact endothelium. In coronary arteries with intact endothelium, addition of 0.01-3.0 microM TRAP, a 14-amino acid residue peptide (SFLLRNPNDKYEPF) homologous to the newly exposed N-terminus after cleavage of the cloned human thrombin receptor, produced rapid, dose-dependent relaxation (Emax = -89.6 +/- 2.3%, n = 26). Threshold concentration was 0.03 microM, and IC50 value was 0.3 microM. Mechanical disruption of the endothelium completely abolished the TRAP-induced relaxation; instead a dose-dependent contraction was observed. Expressed as a percentage of the maximum 70 mM KCl-induced contraction, the maximum contraction observed with 3 microM TRAP was 62.0 +/- 4.1% (n = 32). Pretreatment of endothelium-intact coronary arteries with either 3 microM hemoglobin or 0.25 mM NG-monomethyl-L-arginine (L-NMMA), specific inhibitors of endothelium-derived relaxing factor or nitric oxide (EDRF/NO), also inhibited the relaxation and unmasked the constrictor effect. The pharmacokinetic characteristics of the opposing coronary vascular effects of TRAP are similar to those observed with thrombin, but specific thrombin inhibitors, such as hirudin and D-phenylalanyl-prolyl-L-arginine chloromethyl ketone (PPACK), which inhibit both thrombin relaxant and constrictor effects, had no effect on TRAP-induced responses.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505364     DOI: 10.1097/00005344-199310000-00015

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

1.  Rat proteinase-activated receptor-2 (PAR-2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue.

Authors:  M Saifeddine; B al-Ani; C H Cheng; L Wang; M D Hollenberg
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

Review 2.  Thrombin and vascular inflammation.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  Mol Cell Biochem       Date:  2011-08-23       Impact factor: 3.396

Review 3.  Antiplatelet therapy: thrombin receptor antagonists.

Authors:  Antonio Tello-Montoliu; Salvatore D Tomasello; Masafumi Ueno; Dominick J Angiolillo
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

4.  Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors.

Authors:  Rany T Abdallah; Joo-Seob Keum; Hesham M El-Shewy; Mi-Hye Lee; Bing Wang; Monika Gooz; Deirdre K Luttrell; Louis M Luttrell; Ayad A Jaffa
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

5.  Thrombin activation of proteinase-activated receptor 1 potentiates the myofilament Ca2+ sensitivity and induces vasoconstriction in porcine pulmonary arteries.

Authors:  Jun Maki; Mayumi Hirano; Sumio Hoka; Hideo Kanaide; Katsuya Hirano
Journal:  Br J Pharmacol       Date:  2010-01-28       Impact factor: 8.739

6.  Proteinase-activated receptor-1 (PAR-1) activation contracts the isolated human renal artery in vitro.

Authors:  Michele Tognetto; Michael R D'Andrea; Marcello Trevisani; Remo Guerrini; Severo Salvadori; Lorella Spisani; Carlo Daniele; Patricia Andrade-Gordon; Pierangelo Geppetti; Selena Harrison
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

7.  Mode of action of thrombin in the rabbit aorta.

Authors:  D Godin; F Rioux; F Marceau; G Drapeau
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

8.  Protein targets of inflammatory serine proteases and cardiovascular disease.

Authors:  Ram Sharony; Pey-Jen Yu; Joy Park; Aubrey C Galloway; Paolo Mignatti; Giuseppe Pintucci
Journal:  J Inflamm (Lond)       Date:  2010-08-30       Impact factor: 4.981

9.  Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice.

Authors:  Michael R Preusch; Nicholas Ieronimakis; Errol S Wijelath; Sara Cabbage; Jerry Ricks; Florian Bea; Morayma Reyes; Joanne van Ryn; Michael E Rosenfeld
Journal:  Drug Des Devel Ther       Date:  2015-09-10       Impact factor: 4.162

Review 10.  When the Blood Hits Your Brain: The Neurotoxicity of Extravasated Blood.

Authors:  Jesse A Stokum; Gregory J Cannarsa; Aaron P Wessell; Phelan Shea; Nicole Wenger; J Marc Simard
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.